Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses
E.H. Dyson(Defence Science and Technology Laboratory), E. Diane Williamson(Defence Science and Technology Laboratory), Matthew J. Hepburn(United States Department of the Army), Robert J. Gwyther(Defence Science and Technology Laboratory), Bassam Hallis(Public Health England), Dawn H. Patient(Defence Science and Technology Laboratory), Anya Gregg(Public Health England), Hannah Cuthbertson(Public Health England), Mary Matheson(Public Health England), Andrew J. H. Simpson(University of Hull)
Cited by 6
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
|Cell|2021|1.2k
Detection of Zika Virus in Semen
|Emerging infectious diseases|2016|363